MICHAEL DOWNING: Open Payments
NPI 1639159346 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 37 payments from 7 companies in 2025. Trend: 2023 $627 · 2024 $648 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 10 | $253 |
| Otsuka America Pharmaceutical, Inc. | 8 | $197 |
| E.R. Squibb & Sons, L.L.C. | 8 | $137 |
| Teva Pharmaceuticals USA, Inc. | 3 | $91 |
| ABBVIE INC. | 4 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
| Alkermes, Inc. | 2 | $37 |
Products named: INVEGA SUSTENNA, REXULTI, COBENFY, UZEDY, VRAYLAR, CAPLYTA, ARISTADA.
Industry payments across TX — which companies pay providers there.
